Association between schizophrenia and DRD3 or HTR2 receptor gene variants

European Journal of Human Genetics

Volumn 12, Issue 7, 2004, Pages 535-541

  Baritaki, S ^a   Rizos, E ^b   Zafiropoulos, A ^a   Soufla, G ^a   Katsafouros, K ^b   Gourvas, V ^a   Spandidos, D A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b Second Department of Radiology   (Greece)

Author keywords

Association study; Dopamine; Polymorphism; Receptor; RFLP; Schizophrenia; Serotonin receptor

Indexed keywords

CYTOSINE; DOPAMINE 3 RECEPTOR; GUANINE; NEUROTRANSMITTER RECEPTOR; SEROTONIN 2 RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GREECE; HETEROZYGOTE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; NUCLEIC ACID BASE SUBSTITUTION; PHENOTYPE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RECEPTOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA;

EID: 4043069218     PISSN: 10184813     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201180     Document Type: Article

References (34)

1. Carlsson A, Lindquist M: Effect of chloropromazine and haloperidol on formation of methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxol 1963; 20: 140-144.
2. Seeman P, Lee T: The dopamine-releasing actions of neuroleptics and ethanol. J Pharmacol Exp Ther 1974; 190: 131-140.
3. Pickar D: Prospects for pharmacotherapy of schizophrenia. Lancet 1995; 345: 557-562.
4. Williams J, Owen MJ, Spurlock G et al: Searching for susceptibility genes for schizophrenia: the European Multicentre Association Study. New Trends Exp Clin Psychiatry 1995; 11: 7-12.
5. Baron M: Genetics of schizophrenia and the new millennium: progress and pitfalls. Am J Hum Genet 2001; 68: 299-312.
6. Williams J, Spurlock G, McGuffin P et al: Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet 1996; 347: 1294-1296.
7. Spurlock G, Williams J, McGuffin P et al: European Multicentre Association Study of Schizophrenia: a study of the DRD2 Ser311Cys and DRD3 Ser9Gly polymorphisms. Am J Med Genet 1998; 81: 24-28.
8. Jonsson E, Lannfelt L, Sokoloff P et al: Lack of association between schizophrenia and alleles in the dopamine D3 receptor gene. Acta Psychiatr Scand 1993; 87: 345-349.
9. Yang L, Li T, Wiese C et al: No association between schizophrenia and homozygosity at the D3 dopamine receptor gene. Am J Med Genet 1993; 48: 83-86.
10. Anney RJ, Rees MI, Bryan E et al: Characterisation, mutation detection, and association analysis of alternative promoters and 5′ UTRs of the human dopamine D3 receptor gene in schizophrenia. Mol Psychiatry 2002; 7: 493-502.
11. Warren Jr JT, Peacock ML, Rodriguez LC, Fink JK: An MspI polymorphism in the hyman serotonin receptor gene (HTR2): detection by DGGE and RFLP analysis. Hum Mol Genet 1993; 2: 338.
12. McGuffin P, Owen MJ, Farmer AE: Genetic basis of schizophrenia. Lancet 1995; 346: 678-682.
13. Ross CA: Schizophrenia genetics: expansion of knowledge? Mol Psychiatry 1999; 4: 4-5.
14. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC: Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347: 146-151.
15. Sokoloff P, Levesque D, Martres MP et al: The dopamine D3 receptor as a key target for antipsychotics. Clin Neuropharmacol 1992; 15: 456A-457A.
16. Guo N, Klitenick MA, Tham CS, Fibiger HC: Receptor mechanisms mediating clozapine-induced c-fos expression in the forebrain. Neuroscience 1995; 65: 747-756.
17. Jernigan TL: Neuroanatomical factors in schizophrenia; in Kavanagh DJ (ed): Schizophrenia: an overview and practical handbook. London: Chapman & Hall; 1992.
18. Arinami T, Gao M, Hamaguchi H, Toru M: A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997; 6: 577-582.
19. Himei A, Koh J, Sakai J, Inada Y, Akabame K, Yoneda H: The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and -141C Ins/Del polymorphisms. Psychiatry Clin Neurosci 2002; 56: 97-102.
20. Crocq MA, Mant R, Asherson P et al: Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet 1992; 29: 858-860.
21. Lannfelt L, Sokoloff P, Martres MP et al: Amino acid substitution in the dopamine D3 receptors a useful polymorphism for investigating psychiatric disorders. Psychiatr Genet 1992; 2: 249-256.
22. Griffon N, Crocq MA, Pilon C et al: Dopamine D3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia. Am J Med Genet 1996; 67: 63-70.
23. Ventriglia M, Bocchio Chiavetto L, Bonvicini C et al: Allelic variation in the human prodynorphin gene promoter and schizophrenia. Neuropsychobiology 2002; 46: 17-21.
24. Nothen MM, Cichon S, Propping P, Fimmers R, Schwab SG, Wildenauer DB: Excess of homozygosity at the dopamine D3 receptor gene in schizophrenia not confirmed. J Med Genet 1993; 30: 708- 709.
25. Laurent C, Savoye C, Samolyk D et al: Homozygosity at the dopamine D3 receptor locus is not associated with schizophrenia. J Med Genet 1994; 31: 260.
26. Liao DL, Yeh YC, Chen HM, Chen H, Hong CJ, Tsai SJ: Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2001; 44: 95-98.
27. Segman R, Neeman T, Heresco-Levy U et al: Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999; 4: 247-253.
28. Mant R, Williams J, Asherson P, Parfitt E, McGuffin P, Owen MJ: Relationship between homozygosity at the dopamine D3 receptor gene and schizophrenia. Am J Med Genet 1994; 54: 21-26.
29. Nimgaonkar VL, Zhang XR, Caldwell JG, Ganguli R, Chakravarti A: Association study of schizophrenia with dopamine D3 receptor gene polymorphisms: probable effects of family history of schizophrenia? Am J Med Genet 1993; 48: 214-217.
30. Gaitonde EJ, Morris A, Sivagnanasundaram S, McKenna PJ, Hunt DM, Mollon JD: Assessment of association of D3 dopamine receptor MscI polymorphism with schizophrenia: analysis of symptom ratings, family history, age at onset, and movement disorders. Am J Med Genet 1996; 67: 455-458.
31. Arranz M, Collier D, Sodhi M et al: Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995; 346: 281-282.
32. Nothen MM, Rietschel M, Erdmann J et al: Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet 1995; 346: 908-909.
33. Yu YW, Tsai SJ, Yang KH, Lin CH, Chen MC, Hong CJ: Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine. Neuropsychobiology 2001; 43: 79-82.
34. Smith CAD, Smith G, Wolf CR: Genetic polymorphisms in zenobiotic metabolism. Eur J Cancer 1994; 30a: 1921-1935.